Autoimmune Polyglandular Syndrome Type 2: A Rare Condition in Childhood

Heves Kırmızıbekmez¹, Rahime Gül Yeşiltepe Mutlu¹, Nafiye Demirkıran Urgancı², Ayşe Öner³

¹Zeynep Kamil Obstetrics and Children Education and Research Hospital, Clinic of Pediatric Endocrinology, İstanbul, Turkey
²Şişli Etfal Education and Research Hospital, Clinic of Pediatric Gastroenterology, İstanbul, Turkey
³Academic Hospital, Clinic of Pediatric Nephrology and Rheumatology, İstanbul, Turkey

Abstract

Autoimmune polyglandular syndrome type 2 is defined as the occurrence of Addison’s disease concomitantly with autoimmune thyroid disease and/or type 1 diabetes mellitus. An 11-year-old boy with Hashimoto’s disease, Addison’s disease, celiac disease and Langerhans islet cell autoimmunity is described in this case report. Treatment of an endocrine disease may also trigger the onset of another endocrine disease. This case report underlines the importance of early recognition and treatment of critical endocrine diseases as well as the necessity to investigate pediatric patients with autoimmune diseases for coexisting conditions. Furthermore, the role of psychological stress as an inducer of autoimmunity was also discussed.

Key words: Autoimmune, polyendocrinopathy, management, children

Conflict of interest: None declared
Received: 12.04.2014 Accepted: 18.08.2014

Case Report

An 11-year-old boy was admitted to our clinic with complaints of fatigue, anorexia and weight loss which developed in the past eight months. He also had a history of severe psychological stress prior to the symptoms. Three months before the beginning of symptoms he had driven his father’s car without

Introduction

Autoimmune adrenal insufficiency (autoimmune Addison’s disease) is caused by destruction of the adrenal cortex by cell-mediated immune mechanisms. Addison’s disease may also present in the context of autoimmune polyendocrinopathy syndromes. The occurrence of Addison’s disease with autoimmune thyroid disease and/or type 1 diabetes mellitus is known as autoimmune polyglandular syndrome type 2 (APS-2) (1). The syndrome is associated with HLA-DR3 and/or HLA-DR4 haplotypes. The pattern of inheritance is autosomal dominant and the clinical expression is variable (2,3). APS usually presents in the third to fourth decades of life, with a highest prevalence in middle-aged women (4). The most frequent clinical combination of APS-2 is Addison’s disease and Hashimoto’s disease. Adrenal insufficiency has been reported in 5.3% of patients with Hashimoto’s disease (5). Two to 4% of autoimmune thyroid disease patients have concomitant celiac disease (6).

APS-2 is extremely rare in childhood and data on pediatric patients is limited to individual case reports. In this present report, a prepubertal male patient with Hashimoto’s disease, Addison’s disease, celiac disease and positive autoimmunity for type 1 diabetes is described. The need to investigate pediatric patients with organ-specific autoimmune diseases for coexisting conditions is also stressed.
permission and crashed the car. There was not any physical injury in that accident, but the patient experienced serious psychological distress with the feeling of guilt. His parents also describe him as a sensitive, overly cautious and anxious child. His thyroid stimulating hormone level was found as 12.4 mIU/mL with positive thyroid antibodies and he was diagnosed as a case of subclinical hypothyroidism due to “Hashimoto thyroiditis”. He was prescribed 50 µg/day L-thyroxine (L-T4) therapy. However, despite this treatment, clinical deterioration occurred. He lost 8 kg in body weight within three months.

Physical examination at presentation revealed a blood pressure level of 90/40 mmHg and presence of grade 1 goitre. Height was 141 cm and weight was 32 kg (standard deviation score values were 0.54 and -0.74, respectively). Pubertal findings were consistent with Tanner stage 1. The patient had a suntanned appearance, but there was no marked hyperpigmentation in the skin or mucosa. A low cortisol level accompanied by a high adrenocorticotropic hormone (ACTH) level confirmed presence of primary adrenal insufficiency. Laboratory findings at referral and follow-up visit are presented in Table 1. Thyroid ultrasonography revealed a heterogeneous pattern of the parenchyma with no nodular lesion. The electrolyte imbalance was treated with saline infusion. A diagnosis of adrenal insufficiency was considered and treatment with glucocorticoids (10 mg/m²/day hydrocortisone) and mineralocorticoids (0.1 mg/m²/day fludrocortisone) was started. L-T4 treatment was ceased and started again as soon as the clinical findings improved. A very long-chain fatty acid profile was normal and adrenoleucodystrophia was excluded. Investigation for other associating autoimmune endocrine diseases revealed positive findings for anti-glutamate dehydrogenase, anti-islet cell, anti-gliadin and anti-endomysium antibodies. The oral glucose tolerance test revealed a normal fasting blood glucose level and normal glucose tolerance values (Table 1). Endoscopic biopsy revealed villous atrophy, proliferation of the crypts and increased lymphocytic infiltration, confirming the presence of gluten-sensitive enteropathy (celiac disease).

### Table 1. Biochemical findings of the patient at referral and at 2 months of treatment

|                      | At referral | At 2 months of treatment |
|----------------------|-------------|--------------------------|
| TSH                  | 12.4 mIU/mL | 2 mIU/mL                 |
| Free T4              | 1.5 ng/dL   | 1.4 ng/dL                |
| Anti-TPO             | 1642 U/mL   |                          |
| Anti-TG              | 824 U/mL    |                          |
| Cortisol             | 2.2 µg/dL   |                          |
| ACTH                 | 1456 pg/mL  | 12.4 pg/mL               |
| Na                   | 128 mmol/L  | 141 mmol/L               |
| K                    | 5.8 mmol/L  | 4.2 mmol/L               |
| Glucose              | 79 mg/dL    | 84 mg/dL                 |
| Renin                | >720 µU/mL  | 2.5 µU/mL                |
| Aldosterone          | <15 µg/mL   |                          |
| VLCFA profile        | Normal      |                          |
| DHEA-S               | 2.4 µg/dL   |                          |
| 17-hydroxyprogesterone | 0.12 ng/mL  |                          |
| 1.4 Androstenedione  | <0.1 ng/mL  |                          |
| Total testosterone   | <0.13 ng/mL |                          |
| LH                   | <0.05 mIU/mL|                          |
| FSH                  | 1.0 mIU/mL  |                          |
| LHRH test            | Peak LH: 4.15 mIU/mL | 5.3%                    |
| OGGT glucose (fasting) | 84 mg/dL    |                          |
| OGGT insulin (fasting) | 6.6 mU/L    |                          |
| OGGT glucose (120th min) | 86 mg/dL   |                          |
| OGGT insulin (120th min) | 32 mU/L    |                          |
| Folate               | 43 ng/mL    |                          |
| Vitamin B12          | 571 pg/mL   |                          |
| Iron                 | 191 µg/dL   |                          |
| TiBC                 | 73.6 µg/dL  |                          |
| AST                  | 45 U/L      | 18 U/L                   |
| ALT                  | 72 U/L      | 24 U/L                   |
| Anti-gliadin IgA     | (+)         |                          |
| Anti-GAD             | (+)         |                          |
| Islet cell ab        | (+)         |                          |
| Anti-insulin ab      | (-)         |                          |
| LKM tip 1 ab         | (-)         |                          |
| Smooth muscle ab     | (-)         |                          |

TSH: thyroid-stimulating hormone, TPO: thyroid peroxidase, TG: thyroglobulin, Na: sodium, K: potassium, VLCFA: very long-chain fatty acid, DHEA-S: dehydroepiandrosterenedione-sulphate, LH: luteinizing hormone, FSH: follicle-stimulating hormone, LHRH: luteinizing hormone-releasing hormone, OGGT: oral glucose tolerance test, TIBC: total iron-binding capacity, AST: aspartate aminotransferase, ALT: alanine aminotransferase, GAD: glutamic acid dehydrogenase, ab: antibody, LKM: liver-kidney microsomal.

### Discussion

Our patient was an adolescent boy with a diagnosis of APS-2, a condition which is quite rare in childhood. APS-2 usually occurs in patients 30 to 40 years of age and women are affected three times more than men (4). Acquired adrenocortical insufficiency is also uncommon in children and since symptoms like fatigue, anorexia, nausea, weight loss and cognitive disorders are nonspecific and may be related with other conditions such as hypothyroidism, infections and other systemic diseases, adrenocortical insufficiency at this stage can easily be underdiagnosed in pediatric practice. Hypotension, hypoglycemia and hyponatremia are fairly late manifestations (7). Skin hyperpigmentation may be a clue for primary adrenal...
insufficiency, but it may not be remarkable especially in persons who already have a suntanned skin. Our patient did not have a significant hyperpigmentation either in his skin or in his oral mucosa despite the very high ACTH level. Weight loss is a crucial finding, since it is not expected in hypothyroidism. The complaints of our patient were exacerbated after prescription of L-T4, possibly due to the enhancing effect of T4 on hepatic corticosteroid metabolism. The small increase observed in hemoglobin A1c level after replacement therapy suggested the possibility of subclinical hypoglycemic attacks before the diagnosis of adrenal insufficiency.

After the diagnosis of adrenal insufficiency, investigation for possible coexisting diseases revealed presence of celiac disease and positive autoimmunity for type 1 diabetes. The majority of these patients have an atypical or silent type of celiac disease. This is the main reason why it is often underdiagnosed. Early application of a gluten-free diet and lifelong adherence to this treatment decreases the risk of complications in celiac disease (8). Betterle et al (7) reported that clinically overt disorders are considered to be the tip of the autoimmune iceberg since latent forms are much more frequent. This patient might develop type 1 diabetes during the follow-up period. These conditions are designated as “incomplete APS”. Pancreatic antibodies are present in about 6-20% of patients with Addison’s disease who have no overt type 1 diabetes. However, it is not well known whether or when these patients will develop overt disease (7).

Our patient also had a history of psychological stress followed by nonspecific complaints (e.g. anorexia, fatigue, anxiety and altered school performance) suggesting post-traumatic stress disorder. Recent reports indicate the possible role of psychological stress and the role of the major stress-related hormones in the pathogenesis of autoimmune diseases (9). The majority (up to 80%) of patients were reported to suffer from emotional stress before disease onset (10).

In conclusion, we report this patient with APS-2, a rare condition in childhood. Replacement of thyroid hormone may induce exacerbation of a silent adrenal insufficiency. Further investigations should be performed if the patient’s condition deteriorates rather than improves following the hormone replacement therapy. We also suggest that the long-term follow-up of these patients is very important, as incomplete forms are expected to be more common in childhood.

References

1. Neufeld M, Blizzard RM. Polyglandular autoimmune diseases. In: Pinchera A Doniaich D Feni GF Baschieri L, eds. Symposium on Autoimmune Aspects of Endocrine Disorders. New York: Academic Press, 1980:357-365.
2. Carpenter CCJ, Solomon N, Silverberg SG, Bledsoe T, Northcutt RC, Klenenberg JR, Bennett IL, McGehee Harvey A. Schmidt’s syndrome (thyroid and adrenal insufficiency): a review of the literature and a report of fifteen new cases including ten instances of coexistent diabetes mellitus. Medicine (Baltimore) 1964;43:153-180.
3. Obermayer-Straub P, Manns MP. Autoimmune polyglandular syndromes. Baillieres Clin Gastroenterol 1998;12:293-315.
4. Kahaly GJ. Polyglandular autoimmune syndromes. Eur J Endocrinol 2009;161:11-20.
5. Wiebolt J, Achterbergh R, den Boer A, van der Leij S, Marsch E, Suelmann B, de Vries R, van Haeften TW. Clustering of additional autoimmunity behaves differently in Hashimoto’s patients compared with Graves’ patients. Eur J Endocrinol 2011;164:789-794. Epub 2011 Mar 4
6. Van den Driessche A, Eenkhoorn V, Van Gaal L, De Block C. Type 1 diabetes and autoimmune polyglandular syndrome: a clinical review. Neth J Med 2009;67:376-387.
7. Betterle C, Lazzarotto F, Presotto F. Autoimmune polyglandular syndrome Type 2: the tip of an iceberg? Clin Exp Immunol 2004;137:225-233.
8. Mickiewicz P, Kepczynska-Nyk A, Bednarzczuk T. Coeliac disease in endocrine diseases of autoimmune origin. Endokrynol Pol 2012;63:240-249.
9. Atanackovic D, Novotne U, Freier E, Weber CS, Meyer S, Bartels K, Hildebrandt Y, Cao Y, Kröger N, Brunner-Weinzierl MC, Bokemeyer C, Deter HC. Acute psychological stress increases peripheral blood CD3(+)CD56(+) natural killer T cells in healthy men: possible implications for the development and treatment of allergic and autoimmune disorders. Stress 2013;16:421-428. Epub 2013 Apr 8
10. Stojanovich L, Marisavljevic D. Stress as a trigger of autoimmune disease. Autoimmun Rev 2008;7:209-213. Epub 2007 Nov 29